Investing.comQwen · 实盘不做把握 2/10不做原因:消息已过时
北京时间·🕒 发布 23:36:38·⟳ 抓取 23:37:44 +1m06s·⚡ 决策 08-30 23:44:50 +7m06s·57.8 天前
Arrowhead在ESC 2026展示plozasiran治疗重度高甘油三酯血症SHASTA-3/4三期完整12个月数据，计划年底前提交sNDA
SHASTA-3/4 topline结果已于2026年7月22日由Arrowhead IR正式公告（当日股价+18%），PRV购买和sNDA计划于8月4日公告，8月24日ESC展示预告也已被我方判为不做。本次ESC会议展示仅为已知数据的正式学术呈现，无新增疗效/安全性/监管事实。股价自7月以来已上涨约57%，催化已充分定价。且当前为周六美股休市，即使有边际信息也需等到周一，届时ESC展示已完全消化。
📄 原文Investing.com↗ 原文
Arrowhead plans regulatory filing for plozasiran in sHTG
Up +57% since July, this AI-picked software giant can’t stop rallying PASADENA, Calif. - Arrowhead Pharmaceuticals Inc.…
不做 Arrowhead Pharmaceuticals（ARWR.US）
SHASTA-3/4 topline已于7月22日首发（当日+18%），PRV和sNDA计划8月4日公告，股价自7月已+57%。本次ESC展示为已知数据的学术呈现，无新增疗效/安全/监管事实，催化已充分price-in。周六美股休市，无可执行窗口。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Arrowhead plozasiran SHTG三期SHASTA-3/4 topline于7月22日公告（当日+18%），8月4日公告购买PRV并确认年底提交sNDA。8月30日ESC展示为同一数据的学术会议呈现，无新增事实。股价自7月已+57%（52周高$95.49），催化充分定价。周六美股休市，无可执行窗口。结论：旧闻重述，不做。
消息传播链
- SHASTA-3/4 topline结果首发，当日股价+18%，为本次催化的真正起点市场反应:ARWR当日涨约18%，随后持续上行至52周高$95.49
- 购买PRV并确认年底前提交sNDA，进一步消除监管路径不确定性
- 预告将在ESC 2026展示SHASTA完整数据，我方已判为不做
- ESC展示的AI生成报道，无新增事实，仅为已知数据的媒体重述
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-30 · 影响 none
ESC展示的安全性数据（73% TEAE、8.3% SAE vs 10%安慰剂、3例死亡均判定无关）与topline一致，无新增安全信号；但这不改变事件已旧的事实
检索:ARWR plozasiran safety concerns adverse events pancreatitis risk 原文 ↗
先例如何影响了这次决策
对本次决策的影响:事件已明确为旧闻重述（首发于5周前），无需先例校准涨幅；price-in判断基于实际价格走势（+57%）和传播链，先例不改变结论。
工具执行结果 · 成功 9 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 98 ms
{"result": "search_processed_events:agent query=`arrowhead pharmaceuticals plozasiran shasta phase 3 | arwr severe hypertriglyceridemia esc congress 2026 | plozasiran snda fda filing 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.1/72 小时、1576 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事 - fetch_decision_experience 成功 stock_tools HTTP · 78 ms
{ - stock_quote 降级 stock_tools HTTP · 1,132 ms
取价失败: Futu returned no quote - web_search 成功 Qwen 原生联网搜索 · 48,419 ms
已执行一次搜索（未改写查询），以下为推断属于最近 7 天（2026-08-23 至 2026-08-30）的最相关结果，共 5 条： - web_search 成功 Qwen 原生联网搜索 · 25,046 ms
共找到相关结果，以下是最相关的 8 个（保留来源 URL）： - web_search 成功 Qwen 原生联网搜索 · 22,716 ms
根据单次搜索（未改写、未追加查询），找到以下最相关的 8 个结果： - web_search 成功 Qwen 原生联网搜索 · 36,992 ms
**检索结果（仅保留最近 3 天：2026-08-27 至 2026-08-30）** - kb_search 成功 stock_tools HTTP · 2,921 ms
{ - search_case_library 成功 stock_tools HTTP · 49 ms
{"result": "search_case_library「ARWR.US」—— 与这些标的相关的自家决策案例(本页 12 条,该标的全历史相关记录共 17 条；ENTER 只按该标的自己的腿统计):\n◆ ARWR.US：相关历史决策 17 条 · 其中该标的 ENTER 1 条(5.9%) · 已结算 1 笔 · 胜率 100% · 中位 +3.81% · 均值 +3.81% ⚠️只有 1 笔,样本太薄,只能当线索不能当规律\n↑ 胜率/收益口径:ENTER 当日之后 T+1 开盘入场、次日开盘出场,做空腿已按方向取反(所以正数=这个方向做对了)。统计的只有★那只票自己的腿。\n【对所 - web_search 成功 Qwen 原生联网搜索 · 28,954 ms
**搜索结果（近 30 天内，2026 年 7 月 31 日–8 月 30 日）共筛选出 5 条最相关结果：**
原文全文
展开原文 · 2,169 字
Up +57% since July, this AI-picked software giant can’t stop rallying
PASADENA, Calif. - Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) presented results from two Phase 3 studies of plozasiran for severe hypertriglyceridemia treatment during a session at the European Society of Cardiology Congress 2026 in Munich, according to a company press release statement.
The SHASTA-3 and SHASTA-4 studies met their primary and secondary endpoints. Plozasiran reduced triglycerides by 79% and 81% versus placebo at Month 12 in the respective studies. The trials enrolled 757 patients who received either plozasiran 25 mg or placebo subcutaneously once every three months.
More than 90% of plozasiran-treated patients in both studies achieved triglyceride levels below 500 mg/dL at Month 12, compared with approximately 50% of placebo-treated patients. Over half of plozasiran-treated patients achieved triglyceride levels below 150 mg/dL.
In a pooled analysis, plozasiran reduced acute pancreatitis events by 78% versus placebo. Among patients with triglycerides at or above 500 mg/dL and prior acute pancreatitis history, the treatment reduced the event rate by 91% versus placebo.
Treatment-emergent adverse events occurred in 73% of patients in both plozasiran and placebo groups. Serious adverse events occurred in 8.3% of plozasiran patients and 10% of placebo patients. The most common adverse events in plozasiran-treated patients included worsening glycemic control at 14.3% and diarrhea at 5.6%.
Three fatal events occurred in plozasiran-treated patients, consisting of two cardiovascular deaths and one death from chronic myelomonocytic leukemia. All were attributed to pre-existing conditions and assessed as unrelated to study treatment.
Arrowhead plans to file a supplemental New Drug Application with the FDA by year-end 2026 and intends to use a Priority Review Voucher purchased on August 4, 2026.
Plozasiran is currently approved as REDEMPLO for familial chylomicronemia syndrome treatment in the U.S., Canada, China, Australia, and the European Union.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PASADENA, Calif. - Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) presented results from two Phase 3 studies of plozasiran for severe hypertriglyceridemia treatment during a session at the European Society of Cardiology Congress 2026 in Munich, according to a company press release statement.
The SHASTA-3 and SHASTA-4 studies met their primary and secondary endpoints. Plozasiran reduced triglycerides by 79% and 81% versus placebo at Month 12 in the respective studies. The trials enrolled 757 patients who received either plozasiran 25 mg or placebo subcutaneously once every three months.
More than 90% of plozasiran-treated patients in both studies achieved triglyceride levels below 500 mg/dL at Month 12, compared with approximately 50% of placebo-treated patients. Over half of plozasiran-treated patients achieved triglyceride levels below 150 mg/dL.
In a pooled analysis, plozasiran reduced acute pancreatitis events by 78% versus placebo. Among patients with triglycerides at or above 500 mg/dL and prior acute pancreatitis history, the treatment reduced the event rate by 91% versus placebo.
Treatment-emergent adverse events occurred in 73% of patients in both plozasiran and placebo groups. Serious adverse events occurred in 8.3% of plozasiran patients and 10% of placebo patients. The most common adverse events in plozasiran-treated patients included worsening glycemic control at 14.3% and diarrhea at 5.6%.
Three fatal events occurred in plozasiran-treated patients, consisting of two cardiovascular deaths and one death from chronic myelomonocytic leukemia. All were attributed to pre-existing conditions and assessed as unrelated to study treatment.
Arrowhead plans to file a supplemental New Drug Application with the FDA by year-end 2026 and intends to use a Priority Review Voucher purchased on August 4, 2026.
Plozasiran is currently approved as REDEMPLO for familial chylomicronemia syndrome treatment in the U.S., Canada, China, Australia, and the European Union.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。